Bioprocess Bags Market

USD 4.8 billion in 2026 to USD 21.9 billion by 2036 at a 16.4% CAGR.

• The bioprocess bags market was valued at USD 4.1 billion in 2025.
• Demand is projected to rise from USD 4.8 billion in 2026 to USD 21.9 billion by 2036.
• The market is forecast to record a 16.4% CAGR through 2036, supported by biologics.

What are the defining numbers behind Bioprocess Bags Market growth?

An absolute opportunity of USD 17.1 billion is expected between 2026 and 2036.

• Demand Drivers in the Market
  • Biopharmaceutical companies need sterile bag systems for buffer and media storage since multi-product suites change batches frequently.
  • Development teams need flexible clinical-scale containers. FDA’s March 2026 therapy-approval report stated that CDER approved 46 novel drugs in 2025.
  • European manufacturing teams need scalable product-contact systems. EMA’s June 2026 annual report stated that the agency recommended 104 human medicines in 2025.
  • Cell therapy teams need closed bags that protect harvest and hold steps across short manufacturing windows.
• Key Segments Analyzed
  • By Product: 2D Bioprocess Bags are expected to hold 68.20% share in 2026 because flat formats fit storage and transfer workflows.
  • By Capacity: Small is projected to account for 45.20% share in 2026 due to research, seed-train and low-volume clinical use.
  • By Application: Buffer And Media Storage is anticipated to capture 36.50% share in 2026 owing to repeated preparation and hold steps.
  • By End Use Industry: Biotechnology is estimated to represent 35.00% share in 2026, supported by biologics and therapy manufacturing.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, states, “The commercial test for bioprocess bags is wider than availability. Users want film qualification and extractables documentation before platform approval. Demand is expected to favor suppliers that connect sterile-bag depth with upstream and downstream support.”
• Strategic Implications
  • Biopharma manufacturers should map product-contact fluid paths before replacing stainless-steel hold vessels with disposable bags.
  • Bag suppliers should publish film, weld, connector and sterilization documentation in audit-ready formats.
  • CMOs should qualify alternate film families where material shortages threaten batch schedules.
  • Process engineers should select capacity ranges around real batch volumes and site handling limits.

Germany is expected to record 18.0% CAGR through 2036, supported by pharmaceutical manufacturing depth. Brazil is projected to post 16.4% CAGR as health-industrial policy supports local capacity. The USA is anticipated to advance at 14.8% CAGR due to domestic manufacturing programs. The U.K. is estimated to reach 13.3% CAGR, while Japan is forecast to post 11.7% CAGR through biomanufacturing programs.

2D Bioprocess Bags lead Product at 68.20%; Small leads Capacity at 45.20%.

Which Product dominates?

2D Bioprocess Bags hold 68.20% share in 2026.

2D Bioprocess Bags are expected to lead Product because flat formats are easy to store, freeze and connect. Standard 2D bags serve buffer and media needs. Sartorius expanded cleanroom space to around 9,000 square meters at Aubagne in June 2025 for 2D and 3D single-use bags.

What leads the Capacity segment?

Small capacity leads with 45.20% share in 2026.

Small capacity is projected to account for the main share since clinical batches often need containers below 50 liters. Medium and larger bags remain necessary after scale-up. Extra-large bags serve bulk hold and transport where plants want fewer container changes.

How does Application shape demand?

Buffer And Media Storage holds 36.50% share in 2026.

Buffer And Media Storage is anticipated to lead Application because every bioprocess run needs prepared liquids. Buffer and media storage remain recurring needs across upstream steps. Corning offers single-use bioprocess bags in multiple sizes, film types and connector configurations.

What supports Biotechnology within End Use Industry?

Biotechnology accounts for 35.00% share in 2026.

Biotechnology is estimated to represent the main end-use share because biologic, vaccine and cell-therapy programs rely on closed liquid handling. Biopharmaceutical companies use bags in development and production. Charter Medical lists Bio-Pak, CryoProtect and fluid-transfer bag systems.

Closed processing drives it; film qualification and supply risk restrain it.

Driver Impact Analysis

Opportunity Impact Analysis

Restraint Impact Analysis

• The country comparison spans 6.3 percentage points across the forecast period.
• Germany remains 1.6 percentage points ahead of Brazil through pharmaceutical manufacturing depth and biologics capacity.
• Brazil remains 1.6 percentage points ahead of the USA as health-industrial policy supports local production capability.
• The USA remains 1.5 percentage points ahead of the U.K. through domestic manufacturing programs and biologics approvals.
• The U.K. remains 1.6 percentage points ahead of Japan through life-sciences business density and therapy manufacturing.
• Japan closes the displayed range through biomanufacturing programs and domestic pharmaceutical production depth.

Comparable CAGRs create different entry conditions due to manufacturing base and biologics pipeline mix. Full report coverage includes North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa.

What supports Germany’s lead?

18.0% CAGR, supported by pharmaceutical manufacturing depth and single-use qualification.

Germany Trade & Invest reported in 2026 that pharmaceutical industry sales reached EUR 67.9 billion in 2025. Germany is expected to record 18.0% CAGR through 2036 as biologics suites increase closed storage. The manufacturing base favors qualified 2D and 3D bags.

How is Brazil scaling Bioprocess Bags Market demand?

16.4% CAGR, driven by health-industrial policy and local biologics capacity.

Brazil’s Ministry of Development, Industry, Commerce and Services reported in March 2026 that Plano Mais Produção projects worth BRL 24.99 billion were associated with the New Industry Brazil Health Mission through the third quarter of 2025. Brazil is projected to post 16.4% CAGR through 2036 as vaccine programs expand local bioprocessing needs. Flexible bags fit facilities that scale batches.

What supports the USA outlook?

14.8% CAGR, backed by domestic manufacturing programs and biologics production.

The FDA announced the FDA PreCheck program in August 2025 to facilitate new U.S. pharmaceutical manufacturing facilities and noted that U.S.-based manufacturers accounted for 11% of API manufacturers serving FDA-approved products. The USA is anticipated to advance at 14.8% CAGR through 2036 as domestic manufacturing initiatives support facility readiness. Modular bags support sterile and biologic production setup.

How does the U.K. perform?

13.3% CAGR, supported by life-sciences business density and therapy manufacturing.

The Office for Life Sciences reported in October 2025 that the U.K. life sciences sector included 6,170 businesses in 2023/2024. The U.K. is estimated to reach 13.3% CAGR through 2036 as biopharma users select flexible bag formats. Smaller clinical batches favor controlled bag systems.

What underpins Japan’s growth?

11.7% CAGR, led by domestic pharmaceutical production and biomanufacturing programs.

Japan’s Ministry of Health, Labour and Welfare reported in December 2025 that pharmaceutical production value reached JPY 10.2485 trillion in 2024. Japan is forecast to post 11.7% CAGR through 2036 as drug production supports bioprocess development. Users favor documented bag systems for high-value batches.

Thermo Fisher Scientific and Sartorius maintain direct single-use bioprocess-bag portfolios, while Corning and Saint-Gobain also provide bag, film and assembly solutions.

Thermo Fisher Scientific is active through single-use bioprocess systems, 2D and 3D BioProcess Containers and Bioprocess Design Center support. Sartorius offers Flexsafe 2D and 3D bags across storage, transfer, shipping and other bioprocessing steps. Corning supports configurable single-use systems through multiple bag sizes, film materials, tubing, fittings and connector options.

Charter Medical contributes Fluid Transfer Bags, Bio-Pak small-volume bio-containers and CryoProtect bio-containers. Danaher participates through Cytiva's single-use bioprocess technologies. Entegris offers 2D and 3D bioprocess assemblies and specialized bag films, while Merck KGaA provides Mobius single-use bag assemblies. Avantor adds single-use bag and assembly capability through its acquired RIM Bio business, and Saint-Gobain supplies single-use bioprocess bags, multilayer films and configurable assemblies. Across these suppliers, documented material performance, traceability, customization and supply-support capabilities are important elements of their product offerings.

Thermo Fisher Scientific and Sartorius AG are key providers. Corning Incorporated and Saint-Gobain are also profiled. Charter Medical Ltd., Danaher Corporation, Entegris Inc., Merck KGaA and Avantor, Inc. through its acquired RIM Bio business complete the company set.

• Thermo Fisher Scientific
• Corning Incorporated
• Charter Medical Ltd.
• Danaher Corporation
• Entegris Inc.
• Merck KGaA
• Avantor, Inc. (acquired RIM Bio business)
• Saint-Gobain
• Sartorius AG

• European Medicines Agency. (2026, June 11). Evaluation and monitoring of medicines: Highlights. In Annual report 2025.
• Germany Trade & Invest. (n.d.). The pharmaceutical industry in Germany.
• Merck KGaA. (n.d.). Single-use assemblies.
• Ministério do Desenvolvimento, Indústria, Comércio e Serviços. (2026, March 13). Revisão e implementação de instrumentos para fortalecimento produtivo e tecnológico do Complexo Econômico e Industrial da Saúde (CEIS) [Review and implementation of instruments to strengthen Brazil’s health economic and industrial complex].
• Office for Life Sciences, Department for Science, Innovation and Technology, Department of Health and Social Care, & Department for Business and Trade. (2025, October 2). Bioscience and health technology sector statistics 2023 to 2024.
• Saint-Gobain Life Sciences. (2024). Bioprocess bags: For single-use bioprocess systems [Product brochure].
• Sartorius Stedim Biotech S.A. (2025, June 17). Sartorius Stedim Biotech expands manufacturing and R&D capacities for innovative bioprocess solutions in France.
• Thermo Fisher Scientific Inc. (2025, December 2). Thermo Fisher Scientific deepens investment in Asia’s biopharma ecosystem with expansion of Bioprocess Design Centers.
• U.S. Food and Drug Administration. (2025, August 7). FDA announces new FDA PreCheck program to boost U.S. drug manufacturing.
• U.S. Food and Drug Administration, Center for Drug Evaluation and Research. (2026, January). Advancing health through innovation: New drug therapy approvals 2025 [Report].

• The report explains bag use across product, capacity and application dimensions.
• Segment analysis identifies 2D Bioprocess Bags and Small capacity as the main share positions in 2026.
• Country analysis examines Germany, Brazil, USA, U.K. and Japan using the stated country CAGR values.
• Competitive analysis reviews Thermo Fisher Scientific, Corning, Charter Medical, Danaher, Entegris, Merck KGaA, Avantor, Saint-Gobain and Sartorius.
• Application analysis covers buffer storage, cell culture, chromatography and product hold workflows.

2D bags, 3D bags, process bags and storage bags used for sterile bioprocess fluid handling.

The Bioprocess Bags Market covers flexible single-use bags used for storage, transfer, freezing and hold. It includes formats connected to tubing, manifolds, sensors or ports.

The market differs from broader bioprocess containers coverage because it focuses on bag-based containers within liquid-handling workflows. Related single-use assemblies remain linked when the bag creates the main value in the configuration.

What is included in the scope?

Bioprocess bag systems used in regulated and research biomanufacturing workflows.

The scope includes 2D and 3D bags, storage bags and product-hold bags. It covers buffer storage, cell culture and ultrafiltration. Adjacent cell culture vessels and single-use mixing liners are included where they create bag pull-through inside a workflow.

What is excluded from the scope?

Rigid vessels and general storage containers are outside the scope.

The scope excludes stainless-steel tanks, rigid carboys, glass bottles, bioreactor hardware, laboratory plates and general medical waste bags. Tubing-only assemblies, filters and sensors fall outside the boundary unless sold as part of a bag-centered configuration.

How was the analysis built?

120+ sources, 35+ company portfolios, 25+ countries and more than 20 interviews.

• Primary Research: Interviews include biopharmaceutical manufacturers, CDMOs, single-use system providers, quality teams and process engineers. Discussions examine qualification, batch changeover needs and film selection.
• Desk Research: Desk research covers government statistics, regulator publications, official company pages, product brochures and public policy documents.
• Market Sizing and Forecasting: Market estimates combine biologics pipeline activity, single-use adoption, capacity needs, application mix and country-level growth.
• Data Validation and Update Cycle: Findings are validated by comparing interviews with public data, provider activity, company developments and regulatory changes.

• By Product

  • 2D Bioprocess Bags
  • 3D Bioprocess Bags

• By Capacity

  • Small
  • Medium
  • Large
  • Extra Large

• By Application

  • Buffer And Media Storage
  • Cell Culture
  • Cell Separation And Harvest
  • Ultrafiltration And Diafiltration
  • Intermediate And Final Product Hold
  • Others

• By End Use Industry

  • Biotechnology
  • Pharmaceuticals
  • Material
  • Polyethylene
  • Ethylene Vinyl Acetate
  • Multilayer Films
  • Workflow
  • Upstream Processing
  • Downstream Processing
  • Storage And Transport

• By Region

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia and Pacific
  • Middle East and Africa